Nurix Therapeutics, Inc. Reports First Quarter 2026 Financial Results and Corporate Update

Nurix Therapeutics, Inc. (NASDAQ: NRIX) has released its financial results for the first quarter ended February 28, 2026, accompanied by a corporate update. The results were announced via an official press release dated April 8, 2026.

Key Highlights from the Report

• Net Loss: Nurix reported a net loss of \$87.2 million, or (\$0.79) per share, for the three months ended February 28, 2026. This marks a significant increase from the net loss of \$56.4 million, or (\$0.67) per share, recorded in the same period in 2025. The widening loss is primarily attributed to increased research and development expenses as well as higher general and administrative costs.
• Revenue: Collaboration revenue for the quarter was \$6.3 million, compared to \$18.5 million in the prior year’s quarter. This notable decrease in collaboration revenue may be due to the timing of milestone payments and other contractual receipts from partners.
• Operating Expenses:
  • Research and development expenses rose to \$84.1 million (vs. \$69.7 million in Q1 2025).
  • General and administrative expenses increased to \$81.3 million (vs. \$62.9 million in Q1 2025).
• Cash Position: As of February 28, 2026, Nurix held \$540.7 million in cash, cash equivalents, and marketable securities. This is down from \$592.9 million as of November 30, 2025, reflecting a burn rate that investors should closely monitor.
• Weighted-Average Shares Outstanding: The company had 110,071,668 weighted-average shares outstanding (basic and diluted) for the quarter, up from 83,560,795 in the prior year’s quarter, indicating recent capital raises or share issuances.
• Balance Sheet:
  • Total assets: \$636.1 million (Q1 2026), down from \$688.1 million (FY 2025).
  • Total stockholders’ equity: \$480.9 million (Q1 2026), down from \$538.7 million (FY 2025).

Potentially Price-Sensitive Information for Shareholders

• Significant Increase in Net Loss: The sharp rise in net loss and operating expenses may be viewed negatively by investors, potentially impacting share price. The company’s accelerated investment in R&D and administration suggests a ramp-up in developmental activities, but also increases financial risk.
• Decline in Collaboration Revenue: A drop in collaboration revenue raises concerns regarding the timing and realization of milestone payments. Investors should be aware of the potential impact on future cash flows and overall financial health.
• Cash Burn Rate: The reduction in cash reserves is notable. While the company retains a strong cash position, ongoing high expenditures and declining revenue could pressure the company to seek additional financing or partnerships.
• Share Dilution: The significant increase in shares outstanding may dilute existing shareholder value, especially if further capital raises are needed.

Other Noteworthy Details

• Nurix continues to enroll subjects in its Phase clinical studies, as highlighted in its corporate update, signaling progress in drug development. However, the financial report does not mention any major clinical milestones or regulatory updates in this quarter.
• The company cautions investors about risks related to milestone payments, global macroeconomic conditions, cybersecurity, and regional conflicts, which may affect its operations and financial outlook.
• Nurix is not classified as an emerging growth company, meaning it is subject to full SEC reporting requirements and accounting standards.
• No indication was made of written communications, tender offers, or soliciting materials affecting shareholder rights or obligations.

Summary for Investors

Nurix Therapeutics’ Q1 2026 financial report reveals a widening net loss, declining collaboration revenue, and a shrinking cash position, all of which are key concerns for shareholders. While the company continues to advance its pipeline, the rate of cash burn and potential share dilution may weigh on investor sentiment. Shareholders should closely monitor future developments related to milestone payments, clinical progress, and possible financing activities, as these could significantly impact Nurix’s share value.

Contacts

Investors: Kris Fortner
Nurix Therapeutics, Inc.
Email: [email protected]

Disclaimer: This article is based on Nurix Therapeutics, Inc.’s official SEC filings and press releases. It contains forward-looking statements, which are subject to risks and uncertainties, including those described in Nurix’s SEC filings. Investors should not place undue reliance on these statements and are encouraged to conduct their own due diligence and consult financial advisors before making investment decisions. The information is accurate as of the date of publication and is not intended as investment advice.

View Nurix Therapeutics, Inc. Historical chart here